Management of Baseline Measurements in Statistical Analysis of 2×2 Crossover Trials by Momenyan, Somaye & Alavi Majd, Hamid
 
nal License, NonCommercial 4.0 Internatio-is an open access article under the terms of the Creative Commons Attribution  Journal of Paramdedical Sciences 
13 
Original Article  
Management of Baseline Measurements in Statistical 











Department of Biostatistics, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
2










Introduction: Crossover designs have applications in a wide range of 
sciences. The simplest and most common of such designs are the two-period, 
two-treatment (2×2) crossover. As a consequence, each subject provides a 
4×1 vector of responses for data analysis in the following chronological 
order: baseline (period 1), post-baseline (period 1), baseline (period 2), and 
post-baseline (period 2).  
Methods: We considered three types of analytic approaches for handling the 
baselines:1) analysis of variance (ANOVA) method which ignores the first or 
both period baselines or use a change from baseline analysis 2) analysis of 
covariance (ANCOVA) method which uses an analysis of covariance where 
linear functions of one or both baselines are employed as either period-
specific or period-invariant covariates 3) Joint modeling method that 
conducts joint modeling of a linear function of the baseline and post-baseline 
responses with certain mean constraints for the baseline responses. The 
crossover clinical trial data was analyzed, using the proposed models.                                   
Results: Based on the results on real data among all mentioned models, the 
first model (direct comparison of post-treatment values) and the second 
model (post-treatment measurement subtracts corresponding baseline) had 
the lowest and the highest standard errors, respectively. With respect to 
Akaike Information Criterion (AIC), the fifth model (comparison of post-
treatment values adjusted by all available baseline data) and the eighth model 
(comparison of post-treatment values adjusted by difference and sum of all 
available baseline data) had the lowest magnitude, and the ninth model 
(modeling period baseline jointly with post-treatment values) had the highest 
AIC for both variables which the values of AIC were 518.1, 520.9 and 
1137.8, respectively. 
Conclusion: To sum up, it is found that baseline data of crossover trial may 
be used to improve the efficiency of treatment effect estimation when applied 
appropriately. 
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     Crossover designs have applications in a 
wide range of sciences and research areas, 
such as clinical trials, pharmaceutical 
studies, psychological experiments, 
agriculture field trials, and animal feeding 
experiments [1]. The advantage of such 
designs is that the subjects become their 
own controls, thereby reducing the error 
variance. The simplest and most common of 
such designs are the two-period, two-
treatment (2×2) crossover, with the 
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treatments generically labeled A and B. In a 
typical trial, subjects are randomized in a 
1:1 ratio to either the AB sequence (receive 
treatment A in period 1 and treatment B in 
period 2) or the BA sequence (receive 
treatment B in period 1 and treatment A in 
period 2). A ‘washout’ of suitable length is 
imposed between the two periods to 
minimize the risk of a potential carryover 
effect of the first treatment [2]. For each 
subject, a continuous response of interest 
(e.g., systolic blood pressure) is measured 
before and after a fixed-duration 
administration of the assigned treatment 
within each period. Accordingly, each 
subject provides a 4×1 vector of responses 
for data analysis in the following 
chronological order: baseline (period 1), 
post-baseline (period 1), baseline (period 2), 
and post-baseline (period 2), where baseline 
refers to the pre-treatment response within 
each period. Using these baseline 
measurements can improve the statistical 
power of crossover designs [3].  
With the increasing popularity of crossover 
designs in the past three decades, different 
analytic approaches for modeling baseline 
data in crossover trials have been suggested 
in the literature, such as Hills and Armitage 
[4], Wallenstein [5], Willan and Pater [6], 
Kenward and Jones [2], and the recent work 
by Metcalfe [7] and Kenward and Roger 
[3]. As such, for the 2×2 crossover, four 
types of analytic approaches for handling 
the baselines can be considered: ignore the 
first or both period baselines, use a change 
from baseline analysis (very common), use 
an analysis of covariance where linear 
functions of one or both baselines are 
employed as either period-specific or 
period-invariant covariates, or conduct joint 
modeling of a linear function of the baseline 
and post-baseline responses with certain 
mean constraints for the baseline responses. 
This study reviews all of the models that 
have been presented in different studies on 
2×2 crossover trial until now [2, 3, 5-11]. 
The performance of statistical methods will 
also be investigated in an analysis of real 
data from a crossover study of treatments 
for effectiveness of pistachio nut 
supplementation on High-density 
Lipoprotein (HDL) and Low-density 
Lipoprotein (LDL) measures in patients 
with type 2 diabetes. In this study, no 
carryover effect and unstructured variance-
covariance matrix (Ʃ) was assumed.  
  
 
2. Materials and Methods 
2.1 Modeling methods     
      For each subject, let Xi and Yi denote the 
baseline and post treatment response within 
period i (i = 1, 2), respectively. It is 
assumed that 
11)( XE and 22)( XE for 
both the AB and BA sequences, 
AYE   11)(  and BYE   12)(  for the 
AB sequence, and BYE   11)(  and 
AYE   12)(  for the BA sequence. This 
common formulation allows for the true 
periods 1 and 2 baseline means to be 
different within each sequence, but it 
assumes that the period-specific baseline 
means are the same across the two 
sequences. This is equivalent to assuming 
that there is no [differential] carryover 
effect between periods 1 and 2 for the two 
treatments. In addition, it is assumed that 
the true variance-covariance matrix of the 
4×1 response vector 1 1 2 2( , , , )
TX Y X Y is 
sequence invariant, with the general (i.e., 


























































Different studies have showed that the mean 
of the six within-subject correlations is 
typically in the 0.6–0.9 range, with 
individual correlations ranging from 0.5 to 
0.95. Different methods exist for estimating 
treatment`s effect ( BA   ) and for 
testing 0:0 H versus 0:1 H . All 
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methods yield an unbiased estimator of   
variance of estimates and therefore their 
precisions are different. Three general 
modeling methods to estimate treatment 
effect   have been described as follows:
 
 
Method 1: ANOVA method 
Model 1: direct comparison of post-
treatment values: 
)(2/1ˆ 21 YY   
Model 2: direct comparison of change from 
baseline (post-treatment measurement 
subtracts                 
              Corresponding baseline):  
          ))()((2/1
ˆ
2211 XYXY   
Method 2: ANCOVA method 
 
Model 3: comparison of post-treatment 
values adjusted by trial baseline: 
)|(2/1ˆ 121 XYY   
Model 4: comparison of post-treatment 
values adjusted by corresponding period 
baseline: 
)||(2/1ˆ 2211 XYXY   
Model 5: comparison of post-treatment 
values adjusted by all available baseline 
data   (across different periods) 
simultaneously: 
)|(2/1ˆ 2121 XXYY   
Model 6: comparison of post-treatment 
values adjusted by sum of all available 
baseline data  (across different periods) 
)|(2/1ˆ 2121 XXYY   
Model 7: comparison of post-treatment 
values adjusted by difference of all 
available baseline data    (across different 
periods) 
)|(2/1ˆ 2121 XXYY   
Model 8: comparison of post-treatment 
values adjusted by difference and sum of all 
available baseline data (across different 
periods) simultaneously: 
)),(|(2/1ˆ 212121 XXXXYY   
Method 3: Joint modeling method: 
Model 9: modeling period baseline 
),( 21 XX  jointly with post-treatment values 
),( 21 YY  
Model 10: modeling difference period 
baseline )( 21 XX   jointly with difference 
post-treatment  values )( 21 YY   
 The response vector 1 1 2 2
( , , , )TX Y X Y
is 
assumed to follow a four-vitiate normal 
distribution with 
11)( XE  and 22)( XE for both the AB 
and BA sequences. Subject to these mean 
constraints, the means of 1Y  and 2Y  can be 
estimated within each sequence via a 
standard restricted maximum likelihood 
(REML) approach. All statistical analyses 
were performed in SAS software version 
9.2(SAS Institute, Cary, NC). For more 
accurate comparisons, the results were 
reported with three decimal places. 
2.2 Clinical data 
     Study was conducted to determine the 
effect of pistachio nut supplementation on 
High-density lipoprotein (HDL) and Low-
density lipoprotein (LDL) measures in 
patients with type 2 diabetes [12]. A double 
blinded, randomized, crossover clinical trial 
was carried out in Shahid Beheshti Hospital 
of Qom, Iran, in the period between 
February 2012 and March 2013. The study 
protocol for this data was approved by 
Ethics Committee of Qom University of 
Medical Sciences. Forty-four patients with 
type 2 diabetes met the inclusion criteria 
and were enrolled in the study. 44 diabetic 
patients were equally assigned to groups A 
and B. Patients in group A received a snack 
of 25 g pistachio nuts twice a day for 12 
weeks and group B received a control meal 
without nuts. After 12 weeks of 
intervention, the patients had an 8-week 
washout. Then the groups were displaced, 
and group B received the same amount of 
pistachios for 12 weeks. At the beginning 
and end of the first four weeks and second 
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four weeks, High-density lipoprotein (HDL) 
and Low-density lipoprotein (LDL) were 
measured (Figure 1). Carryover effect was 




3. Results  
     Measurements of the two groups of 
diabetic patients in the first and second 
phase are shown in Table 1. The estimated 
correlations between vectors of HDL 
responses 1 1 2 2
( , , , )TX Y X Y
were range from 
0.74 to 0.83, with a mean of 0.77. Also the 
estimated correlations between vectors of 
LDL responses were range from 0.26 to 
0.85, with a mean of 0.56 that was lower 
than HDL. 
Summary statistics and analysis details of 
all models are shown in Table 2 and 3 for 
HDL and LDL variables respectively.  
Among all models mentioned above, the 
first and the second models had lowest and 
highest standard errors, respectively for 
both variables. With respect to Akaike 
Information Criterion (AIC), fifth and 
eighth models had the lowest magnitude, 
and the ninth model had the highest AIC for 









Table1. Measurements of the two groups of type 2 diabetic patients in the first and second phase 
Parameters  first phase  
Group B control (n=21) Group A pistachio (n=23) 
Before After Differences Before After Differences 
HDL 58.8 ± 9.8 50.5 ± 8.5 8.3 ± 6.7 58.3 ± 10.1 48.93 ± 9.3 9.4 ± 6.6 
LDL 79.1 ± 28.4 88.7 ± 21.4 -9.6 ± 27.1 72.7 ± 25.1 78.8 ± 29.9 -6.3 ± 18.5 
 Second phase 
Group B pistachio (n=21) Group A control (n=23) 
Before After Differences Before After Differences 
HDL 47.1 ± 8.9 54.3 ± 9.6 -7.2 ± 3.7 53.8 ± 9.7 54.4 ± 10.5 -0.6 ± 5.4 
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By considering significant level 0.05, effect 
of pistachio was significant in second and 
fourth models while there were no 
significant effects on other models for HDL 
variable (Table 2). There were no 
significant effects of Pistachio on any 
models for LDL variable but there were 
considerable differences between them 
(Table 3). Moreover, in the fifth and eighth 
model, estimation of the effect of pistachio 
and its standard error were almost identical. 
All models showed almost the same 
estimation of effect of pistachio for both 
variables (Table 2, 3). 
 
 
Table 2. summary statistics and analysis details for High-density lipoprotein (HDL) 
AIC Two-tailed  
p-value )ˆ(ˆ V ̂ 
Type of model  
581.5 0.060 0.790 -1.522 First Model 
548.9 0.021 1.240 -2.954 Second Model 
544.7 0.055 0.791 -1.557 Third Model  
552.3 0.019 1.090 -2.655 Fourth Model 
518.1 0.229 1.013 -1.237 Fifth Model  
521.8 0.102 0.804 -1.344 Sixth Model  
584.9 0.133 0.986 -1.510 Seventh Model 
520.9 0.229 1.013 -1.237 Eighth Model 
1137.8 0.140 0.824 -1.237 Ninth Model 
572.8 0.071 0.817 -1.510 Tenth Model 
 
 
Table 3. summary statistics and analysis details for Low-density lipoprotein (LDL) 
AIC Two-tailed 
p-value )ˆ(ˆ V ̂ 
Type of model  
921.1 0.322 17.528 -17.545 First Model 
922 0.275 18.322 -20.238 Second Model 
908 0.295 17.839 -18.910 Third Model  
917.4 0.275 15.892 -6.510 Fourth Model 
870.6 0.377 18.312 -16.363 Fifth Model  
886.3 0.312 18.149 -18.198 Sixth Model  
915.4 0.381 17.703 -15.661 Seventh Model 
873.4 0.377 18.312 -16.363 Eighth Model 
1666.3 0.372 18.169 -16.363 Ninth Model 
924.4 0.382 17.768 -15.661 Tenth Model 
 
 
4. Discussion  
     Crossover designs are typically used as 
relative to parallel group designs; statistical 
efficiency can be gained through leveraging 
the within-subject correlations among 
responses to different treatments. To 
maximize such gains when baseline (pre-
treatment) responses are collected within 
each period of a crossover, it is imperative 
that careful consideration be given to how 
those data will be used in the analysis. The 
present study has discussed many different 
models to tackle these baseline values 
through focusing on the simple 2×2 
crossover. The real data was the clinical 
study that surveyeed effect of pistachio nut 
supplementation on High-density 
lipoprotein (HDL) and Low-density 
lipoprotein (LDL) measures in patients with 
type 2 diabetes. Diabetes mellitus is a 
chronic disease that affects about 5-10% of 
the world population [13]. Diet and weight 
control are the basic principles in the 
treatment of type 2 diabetes. Nuts contain 
magnesium and monounsaturated and 
polyunsaturated fats, which are supposed to 
improve insulin sensitivity, carbohydrate 
metabolism, and insulin homeostasis [14].  
With respect to the results on standard error 
of effect of pistachio diet on HDL and LDL  
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parameters, a common approach (method 
II) which uses the change values in each 
period is an inappropriate model among of 
all models. 
Mehrotra in his study compared variance of 
different models in different structure of the 
variance-covariance matrix of data. He 
showed that the second model will have a 
larger variance than other models 
theoretically [9]. 
Chen et al. in their study used simulation 
and manifested that the estimated standard 
error of the second model is the largest 
under unstructured variance-covariance 
matrix. They also indicated that the first and 
third models have smallest standard error 
among others [8] whereas in the present 
study, the first and the fourth model had 
smallest standard error. 
Mehrotra also illustrated that under 
compound symmetry structure assumption, 
the first model and under other structures, 
seventh model have lowest variance, 
theoretically [9]. 
The present study results showed the ninth 
model has largest AIC among all models. 
Also, in Mehrotra study, using the ninth 
model was not recommended because of 
type I error rate. He similarly showed that 
using simulation in the tenth and seventh 
models have best Type I error rate and 
power. Moreover, seventh model delivers 
better control of  type I error rate than tenth 
model in small samples [9]. 
Based on between and within period 
correlations, only for LDL, within period 
correlations were upper than between period 
correlations while HDL factor had high 
between and within period correlations. 
Chen et al. in their study showed when data 
are strongly correlated within the same 
period but weakly correlated in different 
periods, the efficiency of all models was the 
high but when between period correlations 
were high, the second and third models had 
low efficiency and joint modeling methods 
had higher efficiency to other models. In 
other words, a unique model can’t be 
chosen as the best model and based on 
different structures of the variance-
covariance matrix, various models will have 
different efficiency [8].  
In this study, only 2×2 crossover design was 
investigated for a real data. It is highly 
recommended that all the methods proposed 
for crossover design compare respect to 
type I error, power, AIC and standard errors 
using simulation. Although our focus has 
been on the 2×2 crossover design, all the 
competing methods can be easily extended 
to higher-order crossover designs and 
according to the different criteria, 
comparison can be conducted among them.  
 
5. Conclusion 
     There is no obviously ‘best’ method to 
tackle baselines for such as a two-period 
crossover design and based on different 
structures of the variance-covariance 
matrix, various models will have different 
efficiency. 
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